Tehran University of Medical Sciences

Science Communicator Platform

Share By
The Footprint of Kynurenine Pathway in Every Cancer: A New Target for Chemotherapy Publisher Pubmed



Ala M1
Authors

Source: European Journal of Pharmacology Published:2021


Abstract

Treatment of cancers has always been a challenge for physicians. Typically, several groups of anti-cancer medications are needed for effective management of an invasive and metastatic cancer. Recently, therapeutic potentiation of immune system markedly improved treatment of cancers. Kynurenine pathway has an interwoven correlation with immune system. Kynurenine promotes T Reg (regulatory) differentiation, which leads to increased production of anti-inflammatory cytokines and suppression of cytotoxic activity of T cells. Overactivation of kynurenine pathway in cancers provides an immunologically susceptible microenvironment for mutant cells to survive and invade surrounding tissues. Interestingly, kynurenine pathway vigorously interacts with other molecular pathways involved in tumorigenesis. For instance, kynurenine pathway interacts with phospoinosisitide-3 kinase (PI3K), extracellular signal-regulated kinase (ERK), Wnt/β-catenin, P53, bridging integrator 1 (BIN-1), cyclooxygenase 2 (COX-2), cyclin-dependent kinase (CDK) and collagen type XII α1 chain (COL12A1). Overactivation of kynurenine pathway, particularly overactivation of indoleamine 2,3-dioxygenase (IDO) predicts poor prognosis of several cancers such as gastrointestinal cancers, gynecological cancers, hematologic malignancies, breast cancer, lung cancer, glioma, melanoma, prostate cancer and pancreatic cancer. Furthermore, kynurenine increases the invasion, metastasis and chemoresistance of cancer cells. Recently, IDO inhibitors entered clinical trials and successfully passed their safety tests and showed promising therapeutic efficacy for cancers such as melanoma, brain cancer, renal cell carcinoma, prostate cancer and pancreatic cancer. However, a phase III trial of epacadostat, an IDO inhibitor, could not increase the efficacy of treatment with pembrolizumab for melanoma. In this review the expanding knowledge towards kynurenine pathway and its application in each cancer is discussed separately. © 2021 Elsevier B.V.
Related Docs
View other Related Docs
1. Tryptophan Metabolites Modulate Inflammatory Bowel Disease and Colorectal Cancer by Affecting Immune System, International Reviews of Immunology (2022)
2. The Footprint of Kynurenine Pathway in Cardiovascular Diseases, International Journal of Tryptophan Research (2022)
3. Recent Progress in the Immunotherapy of Hepatocellular Carcinoma: Non-Coding Rna-Based Immunotherapy May Improve the Outcome, Biomedicine and Pharmacotherapy (2023)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (6)
Mohammad Vaezi (1)
Other Related Docs
4. The Interplay Between Aryl Hydrocarbon Receptor, H. Pylori, Tryptophan, and Arginine in the Pathogenesis of Gastric Cancer, International Reviews of Immunology (2022)
5. Kynurenine Pathway and Its Role in Neurologic, Psychiatric, and Inflammatory Bowel Diseases, Molecular Biology Reports (2023)
6. Clinical Potential of Pd-1/Pd-L1 Blockade Therapy for Renal Cell Carcinoma (Rcc): A Rapidly Evolving Strategy, Cancer Cell International (2022)
7. Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms, Vaccines (2022)
8. Tumor Immunology, Clinical Immunology (2022)
9. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
10. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
11. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
12. The Molecular Mechanism of Actions and Clinical Utilities of Tumor Infiltrating Lymphocytes in Gastrointestinal Cancers: A Comprehensive Review and Future Prospects Toward Personalized Medicine, Frontiers in Immunology (2023)
13. Macrophage’S Role in Solid Tumors: Two Edges of a Sword, Cancer Cell International (2023)
14. Reduced Cish Expression by Sirna Knockdown in Natural Killer Cells Promotes Anti-Tumor Effects Against Gastric Cancer Cell Lines, Discover Oncology (2025)
15. Assessment of Anti-Cancer Effects of Koenimbine on Colon Cancer Cells, Human Antibodies (2020)
16. Nano-Immunotherapy: Overcoming Delivery Challenge of Immune Checkpoint Therapy, Journal of Nanobiotechnology (2023)
17. Ibrutinib-A Double-Edge Sword in Cancer and Autoimmune Disorders, Journal of Drug Targeting (2016)
18. The Pro-Tumorigenic Responses in Metastatic Niches: An Immunological Perspective, Clinical and Translational Oncology (2023)
19. Anti-Cancer Therapeutic Strategies Based on Hgf/Met, Epcam, and Tumor-Stromal Cross Talk, Cancer Cell International (2022)
20. Immune Checkpoint Inhibitor (Ici) Therapy in Central Nervous System Cancers: State-Of-The-Art and Future Outlook, International Immunopharmacology (2025)